Related Experiment Videos
[Myasthenia gravis: treatments and remissions]
Murielle Dunand1, Patrice H Lalive, Natalia Vokatch
1Unité nerf-muscle, Service de neurologie, CHUV, 1011 Lausanne. murielle.dunand@chuv.ch
Revue Medicale Suisse
|June 15, 2007
Summary
Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorder caused by autoantibodies. Treatment aims for remission using symptomatic and immunomodulatory therapies.
Area of Science:
- Neurology
- Immunology
- Pathology
Context:
- Myasthenia gravis (MG) is an autoimmune disorder affecting the neuromuscular junction.
- It is characterized by autoantibodies targeting the nicotinic acetylcholine receptor (AChR) or muscle-specific kinase (MuSK).
- MG predominantly affects young women and elderly individuals, with increasing incidence and prevalence.
Purpose:
- To provide an overview of Myasthenia Gravis.
- To describe the pathophysiology, clinical presentation, and treatment strategies for MG.
Summary:
- MG involves fluctuating muscle weakness, particularly in ocular, facial, and bulbar muscles, with varying severity.
- Disease progression includes remissions and exacerbations.
- The primary treatment goal is complete remission, achieved through symptomatic treatments (anticholinesterases) and immunomodulators (prednisone, azathioprine), alongside collaborative care.
Impact:
- Highlights the importance of early diagnosis and management of MG.
- Emphasizes the need for a multidisciplinary approach involving general practitioners and specialized centers.
- Informs about current therapeutic options for achieving remission in MG patients.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...